IL116323A0 - Tachykinin antagonists their preparation and pharmaceutical compositions containing them - Google Patents

Tachykinin antagonists their preparation and pharmaceutical compositions containing them

Info

Publication number
IL116323A0
IL116323A0 IL11632395A IL11632395A IL116323A0 IL 116323 A0 IL116323 A0 IL 116323A0 IL 11632395 A IL11632395 A IL 11632395A IL 11632395 A IL11632395 A IL 11632395A IL 116323 A0 IL116323 A0 IL 116323A0
Authority
IL
Israel
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
tachykinin antagonists
tachykinin
Prior art date
Application number
IL11632395A
Other languages
English (en)
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9425085.9A external-priority patent/GB9425085D0/en
Priority claimed from GBGB9426016.3A external-priority patent/GB9426016D0/en
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of IL116323A0 publication Critical patent/IL116323A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D411/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
IL11632395A 1994-12-13 1995-12-11 Tachykinin antagonists their preparation and pharmaceutical compositions containing them IL116323A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9425085.9A GB9425085D0 (en) 1994-12-13 1994-12-13 Organic compounds
GBGB9426016.3A GB9426016D0 (en) 1994-12-22 1994-12-22 Organic compounds

Publications (1)

Publication Number Publication Date
IL116323A0 true IL116323A0 (en) 1996-03-31

Family

ID=26306161

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11632395A IL116323A0 (en) 1994-12-13 1995-12-11 Tachykinin antagonists their preparation and pharmaceutical compositions containing them

Country Status (17)

Country Link
EP (1) EP0797583A1 (xx)
JP (1) JPH10511935A (xx)
AR (1) AR001332A1 (xx)
AU (1) AU4343796A (xx)
BR (1) BR9509997A (xx)
CA (1) CA2204130A1 (xx)
CO (1) CO4700289A1 (xx)
CZ (1) CZ179097A3 (xx)
FI (1) FI971685A (xx)
HU (1) HUT77002A (xx)
IL (1) IL116323A0 (xx)
NO (1) NO972526D0 (xx)
PE (1) PE38997A1 (xx)
PL (1) PL320217A1 (xx)
SK (1) SK74697A3 (xx)
TR (1) TR199501568A2 (xx)
WO (1) WO1996018643A1 (xx)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001502311A (ja) * 1996-10-07 2001-02-20 メルク シヤープ エンド ドーム リミテツド 抗鬱及び/又は抗不安薬としてのcns浸透性nk―1受容体拮抗薬
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
EP1930021A3 (en) 1999-02-18 2008-06-18 Kaken Pharmaceutical Co., Ltd. Novel amide derivatives as growth hormone secretagogues
KR101412339B1 (ko) 2004-07-15 2014-06-25 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를차단하기 위한 용도
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
US7956050B2 (en) 2005-07-15 2011-06-07 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
EP1940842B1 (en) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2008039327A2 (en) 2006-09-22 2008-04-03 Merck & Co., Inc. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
PL2336120T3 (pl) 2007-01-10 2014-12-31 Msd Italia Srl Kombinacje zawierające indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy) (PARP)
CA2676357A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1
US8106086B2 (en) 2007-04-02 2012-01-31 Msd K.K. Indoledione derivative
CA2690191C (en) 2007-06-27 2015-07-28 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
WO2009111354A2 (en) 2008-03-03 2009-09-11 Tiger Pharmatech Tyrosine kinase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2010132487A1 (en) 2009-05-12 2010-11-18 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
US9034899B2 (en) 2009-05-12 2015-05-19 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
KR101830447B1 (ko) 2009-05-12 2018-02-20 알바니 몰레큘라 리써치, 인크. 7-([1,2,4]트리아졸로[1,5-α]피리딘-6-일)-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로이소퀴놀린 및 이의 용도
PE20121172A1 (es) 2009-10-14 2012-09-05 Merck Sharp & Dohme Piperidinas sustituidas con actividad en la hdm2
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
CA2805265A1 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
CA2807307C (en) 2010-08-17 2021-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP2632472B1 (en) 2010-10-29 2017-12-13 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
IN2013MN02170A (xx) 2011-04-21 2015-06-12 Piramal Entpr Ltd
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP2844261B1 (en) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
MX363243B (es) 2012-11-28 2019-03-14 Merck Sharp & Dohme Composiciones para tratar cáncer y usos de dichas composiciones.
BR112015013611A2 (pt) 2012-12-20 2017-11-14 Merck Sharp & Dohme composto, e, composição farmacêutica
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US20210277009A1 (en) 2018-08-07 2021-09-09 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164372A (en) * 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
JPH05186498A (ja) * 1991-12-27 1993-07-27 Japan Tobacco Inc プロリン誘導体

Also Published As

Publication number Publication date
TR199501568A2 (tr) 1996-07-21
FI971685A (fi) 1997-08-13
PL320217A1 (en) 1997-09-15
FI971685A0 (fi) 1997-04-18
HUT77002A (hu) 1998-03-02
SK74697A3 (en) 1997-11-05
BR9509997A (pt) 1997-12-30
PE38997A1 (es) 1997-10-02
AU4343796A (en) 1996-07-03
JPH10511935A (ja) 1998-11-17
CO4700289A1 (es) 1998-12-29
EP0797583A1 (en) 1997-10-01
AR001332A1 (es) 1997-10-22
CA2204130A1 (en) 1996-06-20
CZ179097A3 (en) 1997-10-15
NO972526L (no) 1997-06-03
MX9703957A (es) 1997-09-30
WO1996018643A1 (en) 1996-06-20
NO972526D0 (no) 1997-06-03

Similar Documents

Publication Publication Date Title
IL116323A0 (en) Tachykinin antagonists their preparation and pharmaceutical compositions containing them
IL121236A0 (en) Cycloalkano-pyridines their preparation and pharmaceutical compositions containing them
IL119995A0 (en) Pyrido-fused thienyl - and furanyl-oxazolidinones their preparation and pharmaceutical compositions containing them
IL117860A0 (en) Substituted 1-phenyl-3-pyrazolecarboxamides their preparation and pharmaceutical compositions containing them
IL116512A0 (en) Cyclic peptides their preparation and pharmaceutical compositions containing them
IL121235A0 (en) Bicyclic-fused pyridines their preparation and pharmaceutical compositions containing them
IL114622A0 (en) Heteroaryl-oxazolidinones and pharmaceutical compositions containing them
IL122293A0 (en) Substituted 4-phenylaminothiazoles their preparation and pharmaceutical compositions containing them
IL122618A0 (en) Substituted imidazolylacetonitrile compounds their preparation and pharmaceutical compositions containing them
IL111518A (en) Isoquinolines their preparation and pharmaceutical compositions containing them
HUP9904363A3 (en) Piperidine ether muscarinic antagonists and pharmaceutical compositions containing them
IL125710A0 (en) Arylglycinamide derivatives their preparation and pharmaceutical compositions containing them
IL115905A0 (en) Sordarin derivatives their preparation and pharmaceutical compositions containing them
IL115324A0 (en) Neurokinin antagonist compounds their preparation and pharmaceutical compositions containing them
IL119316A (en) Hydroxypyridinones their preparation and pharmaceutical compositions containing them
IL117554A0 (en) Imidazoquinazolines their preparation and pharmaceutical compositions containing them
IL112889A0 (en) Beta-lactams their preparation and pharmaceutical compositions containing them
IL117815A0 (en) Ascomycins their preparation and pharmaceutical compositions containing them
IL123322A0 (en) Tetrahydroquinolines their preparation and pharmaceutical compositions containing them
IL108073A0 (en) Substituted 6-azaandrostenones their preparation and pharmaceutical compositions containing them
IL117817A0 (en) N-subsituted azaheterocyclic compounds their preparation and pharmaceutical compositions containing them
IL125998A0 (en) Taxoids preparation thereof and pharmaceutical compositions containing them
HUP0002929A3 (en) 2-acylaminopropanamines as tachykinin receptor antagonists and pharmaceutical compositions containing the same
IL114623A0 (en) Substituted triazolylmethylphenylnaph-thyridones their preparation and pharmaceutical compositions containing them
IL118672A (en) Benzisothiazolyl-substituted aminomethylchromans their preparation and pharmaceutical compositions containing them